摘要γδ T细胞是T细胞亚群之一，其表面的T细胞受体(TCR)由γ链和δ链组成，不需要与主要组织相容性复合物(MHC)分子结合，并且不需要通过抗原提呈细胞(APC)，可以直接识别并结合抗原分子。部分γδ T细胞能够通过各种机制对肿瘤细胞产生强大的杀伤作用，抑制肿瘤的生长，防止肿瘤的扩散。目前，应用γδ T细胞的过继性细胞免疫疗法已成为血液系统肿瘤治疗的研究热点。γδ T细胞现已在体内、外多种实体瘤细胞中显示出强大的细胞毒作用，表现出明显的治疗优势。但是其应用于治疗血液系统肿瘤的临床研究仍较少，有效性及安全性有待进一步验证。笔者拟就γδ T细胞与血液系统肿瘤相关的基础研究及γδ T细胞现阶段在血液系统肿瘤过继性免疫细胞疗法中的研究现状进行介绍。

abstractsγδ T cell is a subgroup of T cells. T cell receptor (TCR) on its surface consists of the gamma chain and delta chain. It does not need to bind to major histocompatibility complex (MHC) molecules and does not need to present antigen presenting cells (APC), and it can recognize and bind antigen molecules directly. Some γδ T cells exert a powerful killing effect on tumor cells through various mechanisms, inhibiting tumor growth and preventing tumor proliferation. Due to its considerable anti-tumor effect, the adoptive immunocytotherapy with the application of γδ T cells has become a hot research topic in the treatment of various hematologic malignancies. γδ T cells have shown strong cytotoxic activity in a variety of solid tumor cells in vitro and in vivo, showing an obvious therapeutic advantage. However, studies on the treatment of hematologic malignancies are still poor, and the efficacy and safety of these cells in the treatment of hematologic malignancies need to be further verified. This article will review the basic research on the relationship between the γδ T cells and hematologic malignancies and the research status of the γδ T cells in the adoptive immunocytotherapy of hematologic malignancies.